Seres Therapeutics, Inc.
MCRB
$19.44
$1.126.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 64.00K | 374.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 64.00K | 374.00K |
| Cost of Revenue | 26.24M | 27.42M | 23.89M | 21.78M | 23.57M |
| Gross Profit | -26.24M | -27.42M | -23.89M | -21.78M | -23.57M |
| SG&A Expenses | 47.31M | 50.13M | 53.18M | 54.70M | 61.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 110.12M | 114.11M | 121.31M | 129.50M | 144.92M |
| Operating Income | -110.12M | -114.11M | -121.31M | -129.50M | -144.92M |
| Income Before Tax | -53.85M | -60.19M | -125.77M | -144.85M | -134.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.85 | -60.19 | -125.77 | -144.85 | -134.83 |
| Earnings from Discontinued Operations | 139.81M | 133.14M | 125.91M | 119.38M | -27.27M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 85.97M | 72.95M | 136.00K | -25.48M | -162.11M |
| EBIT | -110.12M | -114.11M | -121.31M | -129.50M | -144.92M |
| EBITDA | -105.50M | -109.13M | -115.85M | -123.49M | -138.62M |
| EPS Basic | 11.29 | 9.22 | -0.03 | -4.54 | -23.63 |
| Normalized Basic EPS | -6.86 | -7.59 | -9.00 | -12.49 | -12.31 |
| EPS Diluted | 11.22 | 9.15 | -0.09 | -4.56 | -23.66 |
| Normalized Diluted EPS | -6.86 | -7.59 | -9.00 | -12.49 | -12.31 |
| Average Basic Shares Outstanding | 33.64M | 32.48M | 31.08M | 29.02M | 27.80M |
| Average Diluted Shares Outstanding | 33.66M | 32.49M | 31.08M | 29.02M | 27.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |